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γ-hydroxybendamustine and N-desmethyl-bendamustine, 
at low concentrations, which contribute minimally to cyto-
toxicity. Minor involvement of CYP1A2 in bendamustine 
elimination suggests a low likelihood of drug–drug inter-
actions with CYP1A2 inhibitors. Systemic exposure to 
bendamustine 120 mg/m2 is comparable between adult and 
pediatric patients; age, race, and sex have been shown to 
have no significant effect on systemic exposure in either 
population. The effect of hepatic/renal impairment on 
bendamustine pharmacokinetics remains to be elucidated. 
Higher bendamustine concentrations may be associated 
with increased probability of nausea or infection. No clear 
exposure–efficacy response relationship has been observed.
Conclusions Altogether, the findings support dosing 
based on body surface area for most patient populations.
Keywords Chronic lymphocytic leukemia · Indolent 
B cell non-Hodgkin’s lymphoma · Alkylating agent · 
Pharmacokinetic profile · Systemic exposure
Introduction
Bendamustine hydrochloride is a unique multifunc-
tional alkylating agent with demonstrated clinical activ-
ity against various hematologic malignancies when used 
as monotherapy or in combination with other chemo-
therapeutic agents [1–6]. Administered as an intravenous 
infusion, bendamustine is currently indicated for the 
treatment of chronic lymphocytic leukemia (CLL) and 
indolent B cell non-Hodgkin’s lymphoma (NHL) that has 
progressed during or within 6 months of treatment with 
rituximab or a rituximab-containing regimen [3, 7–9]. 
The recommended bendamustine dose is 100 mg/m2 on 
days 1 and 2 of a 28-day cycle for CLL and 120 mg/m2 
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on days 1 and 2 of a 21-day cycle for relapsed/refractory 
NHL [7].
Although its mechanisms of action have not been fully 
elucidated, bendamustine, like other bifunctional alkyla-
tors, crosslinks DNA and produces single- and double-
strand breaks; however, in vitro studies have demonstrated 
that bendamustine causes more extensive and durable 
breaks than carmustine and cyclophosphamide [10]; has 
incomplete cross-resistance with other alkylators; and leads 
to cell death via apoptosis or mitotic catastrophe [1, 10].
Chemically, bendamustine is 4-[5-[bis(2-chloroethyl)
amino]-1-methyl-benzoimidazol-2-yl]butyric acid hydro-
chloride [11]. Structurally, bendamustine consists of three 
moieties: a mechlorethamine group with alkylating proper-
ties, a butyric acid side chain that increases water solubil-
ity, and a benzimidazole ring that may confer an antimetab-
olite property (Fig. 1) [11–13]. Bendamustine is primarily 
metabolized via hydrolysis of its mechlorethamine group 
into two metabolites with little or no activity: monohy-
droxy-bendamustine (HP1) and dihydroxy-bendamus-
tine (HP2) [7, 14]. Bendamustine also undergoes phase 1 
metabolism via cytochrome P450 (CYP) 1A2-catalyzed 
oxidative pathways, which result in two active circulating 
metabolites: γ-hydroxybendamustine (M3), which was pre-
viously thought to be β-hydroxybendamustine [15, 16], and 
N-desmethyl-bendamustine (M4) [16]. M3 is produced by 
γ-oxidation of the butyric acid side chain, and M4 by dem-
ethylation of the benzimidazole ring [16].
Despite the extensive clinical experience with bendamus-
tine, its overall pharmacokinetics, pharmacokinetic/pharma-
codynamic relationships, and drug–drug interactions have 
only recently been described. This report provides a compre-
hensive overview of data characterizing the pharmacokinet-
ics and pharmacokinetic/pharmacodynamic relationships of 
bendamustine and its circulating active metabolites in adult 
and pediatric patients with hematologic malignancies. A 
MEDLINE search for “bendamustine AND (pharmacokinet-
ics OR pharmacodynamics)” was conducted, and the result-
ing citation list was reviewed for relevant data to be included 
in this paper. In addition, data on file from the preclinical and 
clinical development programs, including modeling analyses, 
were evaluated for possible relevance and inclusion. Specific 
datasets included a human mass balance study and population 
pharmacokinetic analyses in adult and pediatric patients.
Overall pharmacokinetic profile
As shown by a population pharmacokinetic analysis from 
a phase 3 study in patients with rituximab-refractory, indo-
lent B cell NHL and a human mass balance study [17, 18], 
bendamustine is metabolized via multiple pathways, has 
a short effective t1/2 (~40 min) with the maximum plasma 
concentration (Cmax) typically reached near the end of the 
infusion period (~1 h), and a low ratio of concentration at 
12 h to Cmax (mean 1:25,000). Thus, although the pharma-
cokinetics of multiple-dose administration of bendamustine 
have not been studied, dose accumulation is not expected 
with the standard dosing schedule of two consecutive days 
in a 21- or 28-day cycle. Therefore, the single-dose phar-
macokinetic profile is considered representative of the mul-
tiple-dose pharmacokinetic profile [17, 18].
Fig. 1  Bendamustine and its 
main metabolites. Reproduced 
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Distribution
In vitro, approximately 95 % of bendamustine is pro-
tein bound (mostly to albumin) [7, 19]. Data suggest that 
bendamustine is not likely to displace or be displaced by 
highly protein-bound drugs [19].
In mice administered [14C]bendamustine, tissue levels 
of radioactivity were substantially higher in the liver and 
kidneys—two highly perfused organs involved in the clear-
ance of bendamustine and its metabolites—than other tis-
sues [20]. In human adults, the mean steady-state volume 
of distribution for bendamustine was estimated in two 
studies to be ~25 L [17] and 20 L [18], which, consistent 
with murine radioactivity findings, indicates that the drug 
is mainly confined to the extracellular fluid and not exten-
sively distributed to tissues [7]. This pattern of distribution 
is also consistent with the effectiveness of bendamustine 
in inhibiting the growth of lymphoma tumors in xenograft 
models [21, 22].
Metabolism
Bendamustine is primarily hydrolyzed (mainly nonenzy-
matically) to the much less active HP1 and HP2 [7, 14, 23]. 
Bendamustine is also metabolized by CYP1A2 enzymes to 
active M3 and M4 [16, 23], which reach their maximum 
concentrations at or near the same time as the parent drug 
[17]. The potency of M3 is approximately equivalent to 
that of bendamustine, although that of M4 is five- to ten-
fold less than that of the parent drug [16]. Because plasma 
concentrations of M3 and M4 are only 1/10 and 1/100 that 
of bendamustine, respectively [17], the contribution of M3 
and M4 to the therapeutic activity of bendamustine would 
be expected to be minimal [7, 16, 18]. In addition, these 
low plasma concentrations suggest that hepatic metabolism 
via the CYP1A2 oxidative pathways plays a minor role 
[23].
Most metabolic pathways for bendamustine were origi-
nally observed in rats, such as hydrolysis (the primary 
metabolic process), cysteine conjugation of the mechlore-
thamine moiety, and N-demethylation and γ-hydroxylation 
of the benzimidazole and butyric acid moieties, respec-
tively [24].
Analyses of urine samples from the human mass balance 
study were conducted to more fully characterize the metab-
olite profile of bendamustine [23]. Urine samples collected 
2 h after the start of [14C]bendamustine infusion were used 
because they were found to have the highest concentrations 
of radioactivity. Radiochromatograms of these samples 
revealed a total of 25 bendamustine-related compounds as 
well as bendamustine. The majority of the metabolites that 
were detected were present only during the early periods 
of sample collection. [14C]Bendamustine-derived materials 
that were detectable in late urine samples (up to 168 h after 
the infusion) included products of dihydrolysis and cysteine 
conjugation of bendamustine and γ-hydroxybendamustine.
Although a few new metabolic products were detected 
in the human mass balance study that had not been 
observed in rats, those products were largely found to rep-
resent adducts that formed by reaction of bendamustine 
with endogenous compounds in the urine, e.g., phosphate, 
creatinine, and uric acid. These reactions were reproduced 
in vitro by incubation of bendamustine with urine from a 
drug-naïve subject.
Overall, these findings indicate that the metabolic elimi-
nation of bendamustine is qualitatively the same in humans 
and rats [23].
Elimination
The plasma concentration versus time profile of bendamus-
tine declines in a polyphasic manner in the phase 3 popu-
lation pharmacokinetic study and the human mass balance 
study, with an effective t1/2 of ~40 min [17, 18]. The active 
metabolites M3 and M4 have a t1/2 of similar magnitude [7, 
16, 18].
In the population pharmacokinetic model, bendamus-
tine declined from Cmax in a triphasic manner, with an 
intermediate elimination t1/2 of ~40 min and a slow termi-
nal t1/2 of ~110 h [17]. The last phase was only measured 
after the introduction of advanced technology that allowed 
for detection of very low concentrations of bendamustine. 
Because the terminal elimination phase represents a small 
portion of the overall systemic exposure of bendamus-
tine (<1 %), the intermediate t1/2 is considered the effec-
tive t1/2 of bendamustine [17]. The human mass balance 
study showed a similar rapid initial distribution phase and 
effective t1/2. Although the slow terminal phase was not 
observed in the mass balance study, this was probably due 
to the fivefold higher lower limit of quantitation for the 
method used [18].
Concentrations of M3 and M4 declined in biphasic 
and monophasic manners with elimination t1/2 of ~3 and 
~0.7 h (and plasma levels generally undetectable by ~13 
and ~5 h), respectively, in the population pharmacokinetic 
model [17]. In the human mass balance study, the elimina-
tion t1/2 for M3 and M4 were similar (~1.6 and ~0.5 h) [18].
During the 168-h period, after the infusion of [14C]ben-
damustine in the human mass balance study, the mean total 
recovery of radioactivity in excreta was 76 %, of which 
~50 % was recovered in urine and ~25 % in feces. In 24 h 
after the start of the infusion, ~3 % of the dose was recov-
ered in urine as bendamustine, <1 % each was recovered 
as M3 and M4, and ~5 % was recovered as HP2 [18, 23]. 
The high and persistent levels of total radioactivity in urine 
(~36 % of radiochemical dose after 24 h) and plasma (mean 
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terminal t1/2 of 197 h after 168 h) compared with those of 
bendamustine, M3, M4, and HP2 are not uncommon for 
alkylating agents [25] and indicate the presence of addi-
tional longer-lived adducts. As shown in the human mass 
balance study, bendamustine is extensively metabolized, 
primarily via non-enzymatic hydrolysis. Renal or hepatic 
impairment would, therefore, not be expected to have an 
important effect on the systemic exposure to bendamustine, 
due to the short t1/2, dosing schedule, primary metabolic 
pathways, and the very low renal excretion of bendamus-
tine [18, 23].
Comparison of adult and pediatric 
pharmacokinetic profiles
At present, bendamustine is not indicated for the treat-
ment of pediatric acute leukemia, but the pharmacoki-
netic profiles between adult and pediatric populations are 
similar.
Bendamustine monotherapy was recently investigated in 
an international, open-label, single-arm, multicenter, phase 
1/2 study of heavily pretreated pediatric patients aged 
1–20 years with relapsed/refractory acute lymphoblastic 
leukemia (ALL) or acute myeloid leukemia (AML) [26]. 
Secondary study objectives included determining the pedi-
atric pharmacokinetic profile of bendamustine relative to 
the adult pharmacokinetic profile [27].
Systemic exposure to bendamustine 120 mg/m2 in chil-
dren was similar to that previously reported in the phase 
3 adult NHL study [17, 27]. In the 120 mg/m2 pediat-
ric group (n = 38), mean Cmax was 6806 ng/mL (mean 
tmax, 1.1 h) and mean area under the curve (AUC)0–24 was 
8240 ng h/mL, compared with a mean Cmax of 5746 ng/
mL and mean AUC0–24 of 7121 ng h/mL in adults (n = 78) 
[26, 27].
As with adults, the Cmax of bendamustine 120 mg/m2 
in pediatric patients was reached by the end of infusion 
(~1 h). The pediatric pharmacokinetic profile for benda-
mustine showed a very rapid distribution phase after the 
peak plasma concentration, followed by a somewhat slower 
drug elimination phase. The third phase decline, which 
has been observed in adults and represents <1 % of overall 
AUC, could not be adequately shown in the pediatric study 
due to limited sampling (no samples were collected in the 
12–24 h timeframe, with few samples at later time points) 
[27].
Bendamustine dosing paradigm
Bendamustine dosing is based on body surface area 
(BSA) to reduce interindividual variability in drug 
concentrations and to achieve comparable systemic expo-
sure across patients. Recent data confirm the appropriate-
ness of a BSA-based dosing scheme for bendamustine 
[27].
A population pharmacokinetic analysis in 43 pediatric 
patients with acute leukemia who received bendamus-
tine (120 mg/m2, n = 38; 90 mg/m2, n = 5) in the phase 
1/2 pediatric study demonstrated comparable systemic 
exposure and little difference (<15 %) in median benda-
mustine AUC and Cmax across BSA quartiles, despite a 
wide range of BSAs (0.49–1.86 mg/m2) (Fig. 2) [27]. No 
dose-limiting toxicities were reported [26]. Because sys-
temic exposure to bendamustine 120 mg/m2 was similar 
between adult and pediatric patients—with mean AUC0–24 
and Cmax values <16 % higher in the pediatric patients 


























































Fig. 2  Effect of body surface area on systemic exposure. a The line 
represents a linear regression. b Boxes are 25th, 50th, and 75th per-
centiles; whiskers are 5th and 95th percentiles. The numbers above 
the box represent the number of patients. Pediatrics panel: adapted 
with permission of Informa Healthcare [27]
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population—higher doses were not assessed in the pediat-
ric study, per protocol [17, 27].
Effect of selected covariates on the 
pharmacokinetics of bendamustine in adult 
and pediatric patients
The potential impact of age, sex, race, and hepatic or renal 
impairment on the pharmacokinetics of bendamustine has 
been assessed in both adult and pediatric patients using 
population pharmacokinetic analysis. Available evidence 
does not suggest significant differences based on age, sex, 
or race. Mild hepatic and renal impairment did not show 
significant effects on the pharmacokinetics of bendamus-
tine; however, some differences in systemic exposure can-
not be ruled out.
Within the population pharmacokinetic analysis, covar-
iates were assessed using forward selection and back-
ward elimination procedures [17]. A model was created 
and individual concentration–time profiles and pharma-
cokinetic parameters were generated using the Bayes-
ian approach. Individual systemic exposures (expressed 
as Cmax and AUC) were then compared between adult 
and pediatric patients [17, 27]. Because data from the 
adult and pediatric population pharmacokinetic analyses 
were limited for certain covariates, definitive conclusions 
regarding the potential impact of those covariates could 
not be drawn.
Effect of age on systemic exposure to bendamustine
Overall data from adult and pediatric studies provide evi-
dence that age is not an important determinant of systemic 
exposure to bendamustine [17, 27].
Adult patients
In the phase 3 study in adults with NHL, the median ben-
damustine Cmax and AUC showed little difference (<6 %) 
among three age groups (16–64, 65–74, and ≥75 years) 
following bendamustine 120 mg/m2 (Fig. 3). In a model 
based on that study, the predicted means for Cmax and 
AUC0–24 across the entire age range were 5746 ng/mL and 
7121 ng h/mL, respectively [17, 27].
Pediatric patients
Similarly, median bendamustine AUC and Cmax var-
ied by <20 % across all age groups (1–6, 7–11, and 
12–21 years) in the pediatric study (Fig. 3) [27]. Further-
more, mean Cmax and AUC0–24 across the entire age range 
in the pediatric study were 6806 ng/mL and 8240 ng h/mL, 
respectively, which were comparable to those of the adult 
population [27].
Effect of sex on systemic exposure to bendamustine
The sex of adult or pediatric patients has been shown 
to have no significant effect on systemic exposure to 
bendamustine.
Adult patients
In the phase 3 adult NHL study, there were no notable dif-
ferences between median bendamustine AUC and Cmax 




































































Fig. 3  Effect of age on systemic exposure. Boxes are 25th, 50th, and 
75th percentiles; whiskers are 5th and 95th percentiles. Asterisks are 
data points outside this range. The numbers above the box represent 
the number of patients. Pediatrics panel: adapted with permission of 
Informa Healthcare [27]
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Pediatric patients
Sex differences in median bendamustine AUC and Cmax 
levels in the pediatric population pharmacokinetic analysis 
did not meet the prespecified significance level in the popu-
lation analysis. However, the levels were lower by 26 and 
16 %, respectively, in male compared with female patients 
[27]. The reason for the apparent higher exposure in female 
patients remains unknown [27].
Effect of race on systemic exposure to bendamustine
Race appears to have no significant effect on systemic 
exposure to bendamustine.
Adult patients
There were too few non-Caucasian patients in the phase 
3 NHL study to draw any conclusions regarding the influ-
ence of race on bendamustine systemic exposure in adults 
[17]. However, there was no evidence of any differences 
in pharmacokinetic properties among the different race 
groups, including black (n = 5), Asian (n = 1), and His-
panic (n = 1) patients. The pharmacokinetic profiles of 12 
Japanese patients with relapsed/refractory NHL or mantle 
cell lymphoma who received bendamustine 120 mg/m2 
alone (n = 6; Cmax 8.6 μg/mL, AUC0–t 10.2 μg h/mL) or 
in combination with rituximab (n = 6; Cmax 5.4 μg/mL, 
AUC0–t 6.1 μg h/mL) were demonstrated to be similar to 
that of patients in the phase 3 adult NHL study (n = 78; 
Cmax 5.8 μg/mL, AUC0–t 13.6 μg h/mL) [17, 28, 29].
Pediatric patients
In the pediatric study of bendamustine 120 mg/m2, median 
AUC and Cmax values in Caucasians (n = 20) and Asians 
(n = 11) were within <5 % of each other [27]. Although 
bendamustine systemic exposure was ≤30 % lower in non-
Caucasian/non-Asian patients (n = 7, most of whom were 
black or Hispanic) than in Caucasian and Asian patients, 
the difference did not meet the prespecified level of signifi-
cance for bendamustine pharmacokinetic parameters.
Effect of hepatic impairment on systemic exposure 
to bendamustine
The effect of hepatic impairment on the pharmacokinetics 
of bendamustine remains to be fully elucidated. Although 
no significant change in bendamustine clearance has been 
noted in patients with mild hepatic impairment [7, 17], 
some differences in bendamustine systemic exposure in 
this population cannot be ruled out. Due to limited data, 
the current recommendation is for bendamustine to be used 
with caution in patients with mild hepatic impairment and 
not to be used in patients with moderate hepatic impairment 
(aspartate aminotransferase [AST] or alanine aminotrans-
ferase [ALT] 2.5–10 × upper limit of normal [ULN] and 
total bilirubin 1.5–3 × ULN) or severe hepatic impairment 
(total bilirubin >3 × ULN) [7].
Adult patients
In the adult NHL phase 3 study, the pharmacokinetic pro-
file of bendamustine in 26 patients with mild hepatic 
impairment (defined as total bilirubin ≤ULN, AST ≥ ULN 
to 2.5 × ULN, and/or alkaline phosphatase ≥ULN to 
5.0 × ULN) was not substantially different from that in 52 
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Fig. 4  Effect of hepatic impairment on systemic exposure. Boxes are 
25th, 50th, and 75th percentiles; whiskers are 5th and 95th percen-
tiles. Asterisks are data points outside this range. The numbers above 
the box represent the number of patients. Pediatrics panel: adapted 
with permission of Informa Healthcare [27]
1149Cancer Chemother Pharmacol (2015) 75:1143–1154 
1 3
bendamustine tolerability was found to be adequate in a 
pilot study of six patients with advanced bile duct cancer 
and substantial hepatic dysfunction (bilirubin ≤ 3 × UNL) 
[30]. Furthermore, two patients with severe liver impair-
ment and aggressive NHL were recently reported to have 
been successfully treated with bendamustine and rituximab 
[31]. Their total serum bilirubin levels were 10 × ULN, 
but improved greatly after treatment; mild-to-moder-
ate increases in ALT and AST levels in both cases also 
improved following treatment. The liver impairment in 
both patients was considered obstructive rather than func-
tional [31].
Pediatric patients
In the pediatric population pharmacokinetic analysis, a dif-
ference of ≤5 % was observed in the median bendamustine 
AUC0–24 and Cmax in the 23 patients with normal hepatic 
function and the 13 patients with mild hepatic impairment. 
Patients with moderate hepatic impairment (n = 2) had 
higher bendamustine systemic exposure (Fig. 4) [27].
Effect of renal impairment on systemic exposure 
to bendamustine
The effect of renal impairment on the pharmacokinetics 
of bendamustine remains to be fully elucidated. Although 
no significant change in bendamustine clearance has been 
noted in patients with mild-to-moderate renal impairment 
[7, 17], some differences in bendamustine systemic expo-
sure in this population cannot be ruled out. Given that only 
~3 % of the bendamustine dose is eliminated renally, renal 
impairment would be unlikely to have a substantive effect 
on bendamustine systemic exposure [18, 32]. However, due 
to limited data, the current recommendation is for benda-
mustine to be used with caution in patients with mild-to-
moderate renal impairment and not to be used in patients 
with creatinine clearance (CrCL) <40 mL/min [7].
Adult patients
In the adult phase 3 NHL study, there was no meaning-
ful difference in the pharmacokinetics of bendamustine 
among the 31 patients with mild or moderate renal impair-
ment (CrCL, 30–80 mL/min) [7, 17] and the 47 patients 
with normal renal function (Fig. 5). In addition, a mye-
loma study showed no differences in the plasma kinet-
ics of bendamustine or its metabolites between patients 
with normal renal function (n = 12) and those with renal 
insufficiency (n = 12, including 5 who were under con-
tinuous hemodialysis), with only a moderate increase in 
the frequency of myelotoxicity observed in the renally 
impaired group, and no dose reductions were required [32]. 
A retrospective safety assessment in NHL and CLL of 
104 renally impaired patients (CrCL of <40 mL/min) and 
836 patients with CrCL ≥40 mL/min showed no signifi-
cant differences in laboratory toxicities between the CrCL 
groups [33]. Renally impaired patients were found to have 
a twofold increase in the risk of two evaluated grade 3–4 
adverse events compared with patients who had a CrCL 
≥40 mL/min: increased blood urea nitrogen for CLL and 
NHL together (P = 0.02), and thrombocytopenia in a suba-
nalysis of NHL patients with a CrCL <40 mL/min versus 
those with NHL and a CrCL ≥60 mL/min (P = 0.025) 
[33]. Likewise, in two prospective clinical studies [34, 35] 

















































































Fig. 5  Effect of renal impairment on systemic exposure. Boxes are 
25th, 50th, and 75th percentiles; whiskers are 5th and 95th percen-
tiles. Asterisks are data points outside this range. Triangles show indi-
vidual data points for patients with mild renal dysfunction. The num-
bers above the box represent the number of patients. Pediatrics panel: 
adapted with permission of Informa Healthcare [27]
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moderate-to-severe renal impairment or renal failure/dialy-
sis, bendamustine in combination with other drugs (pred-
nisone and bortezomib, or thalidomide and dexametha-
sone) was well tolerated.
Pediatric patients
In pediatric patients, no differences in dose-normalized 
bendamustine pharmacokinetics were observed between 
those with mild renal impairment (n = 3), as defined by 
glomerular filtration rate per National Kidney Foundation 
2002 age-based guidelines [37], and normal renal function 
(n = 40) (Fig. 5) [27].
Potential for CYP interactions with bendamustine
Because bendamustine is primarily biotransformed via 
hydrolysis [7, 14, 23], there is limited potential for direct 
drug interaction.
Based on in vitro data, bendamustine has a low poten-
tial to affect drug metabolism via human cytochrome P450 
enzymes. At concentrations up to 200 μM, bendamustine 
did not inhibit the metabolism of substrates specific for 
isoenzymes CYP1A2, CYP2C9/10, CYP2D6, CYP2E1, or 
CYP3A4/5, and at up to 100 μM, it showed no potential 
for induction of CYP enzymes [7].
However, the M3 and M4 metabolites, both of which 
make little contribution to the cytotoxicity of bendamus-
tine [7, 16, 18], are formed by CYP1A2 [16]. As a result, 
systemic exposure to bendamustine in the presence and 
absence of CYP1A2 inhibitors and inducers was evaluated. 
A comparison between the observed bendamustine con-
centration–time profile following coadministration with a 
CYP1A2 inhibitor (e.g., allopurinol, famotidine, ranitidine, 
or ciprofloxacin) in 15 patients or with a CYP1A2 inducer 
in two patients was similar to that following administra-
tion without a CYP1A2 inhibitor/inducer, which confirms 
that oxidative metabolism by CYP1A2 is a relatively minor 
contributor to the elimination of bendamustine (Fig. 6).
Bendamustine exposure–response relationship
Data suggest that Cmax is an essential component of the 
activity of bendamustine.
The excess of B cells associated with CLL is caused 
by a decrease in apoptosis rather than an increase in cell 
proliferation [38–41]. In vitro, bendamustine has been 
shown to induce apoptosis in a dose- and time-dependent 
manner in B-CLL lymphocytes, and elevated plasma con-
centrations seem to be more relevant than prolonged expo-
sure [42]. Ex vivo studies conducted to assess the effect of 
bendamustine on leukemic cells in CLL have shown that 
the median lethal dose (LD50) of bendamustine is 4.3 μg/
mL in cells from previously treated patients and 7.4 μg/
mL in cells from previously untreated patients [42]. In the 
adult relapsed/refractory NHL phase 3 study, bendamus-
tine 120 mg/m2 resulted in a peak exposure of ~6 μg/mL 
(within the LD50 range) [17].
Adult patients with NHL
The pharmacokinetic profile of bendamustine and expo-
sure–response relationships were described in 80 patients 
































Fig. 6  Pharmacokinetics in presence or absence of CYP1A2 inhibitors/
inducers. Boxes are 25th, 50th, and 75th percentiles; whiskers are 5th 
and 95th percentiles. The numbers above the box represent the number 





















Fig. 7  Kaplan–Meier plot of PFS, stratified by median bendamustine 
AUC. With kind permission from Springer Science+Business Media: 
Figure 5 [17]
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120 mg/m2 [17]. Eighty-five percent of the patients had at 
least a partial response following treatment with bendamus-
tine, but there were no significant associations between any 
of the measures of exposure (e.g., bendamustine AUC and 
Cmax) and treatment response or duration of response. A 
separate trend was noted in progression-free survival based 
on bendamustine AUC value above and below the median 
value (P = 0.3025; Fig. 7).
Pediatric patients with acute leukemia
The population pharmacokinetic and pharmacodynamic 
analysis in 43 heavily pretreated pediatric patients explored 
the exposure–response relationship in the 38 patients who 
received single-agent bendamustine at 120 mg/m2 and were 
evaluable for efficacy in this dose-ranging/safety study 
[27]. Of the 22 patients receiving 120 mg/m2 with a defined 
best overall response, 9 % achieved a partial response, 
32 % had stable disease, and 59 % had progressive disease. 
The remaining five patients received bendamustine 90 mg/
m2, two of whom achieved a complete response (both with 
ALL) [26]. Although no clear exposure–response relation-
ship was observed in the efficacy analysis [27], two ALL 
patients with partial response as their best overall response 
had slightly higher bendamustine AUC and Cmax values 
than the median systemic exposures of patients with stable 
or progressive disease [26]. No patients with AML had a 
response. Furthermore, the median bendamustine AUC and 
Cmax for the 16 AML patients were 17 and 16 % lower, 
respectively, than for the 22 ALL patients. Response data 
for the study population suggest that single-agent benda-
mustine has some activity in heavily pretreated patients 
with relapsed and refractory ALL, but not in AML [27].
Bendamustine safety–exposure relationships
The relationship between bendamustine systemic exposure 
and specific adverse events during treatment was evaluated 
in the adult and pediatric population pharmacokinetic anal-
yses [17, 27]. Significant correlations were observed only 
for nausea in the adult population and infection (e.g., asper-
gillosis, paronychia, sinusitis, and staphylococcal infection) 
in the pediatric population. It should be noted that although 
nausea was evaluated in both studies, it was not shown 
to be associated with bendamustine systemic exposure in 
pediatric patients.
Adult patients with NHL
The correlation between exposure and safety was reported 
in 80 patients who received bendamustine 120 mg/m2 in 
the adult NHL phase 3 trial [17]. Among the five safety 
endpoints of interest (i.e., neutropenia, thrombocytope-
nia, nausea, vomiting, and fatigue), only nausea was found 
to be significantly correlated with bendamustine Cmax 
(P = 0.013), with the probability of nausea increasing 
along with bendamustine Cmax.
The high rate of prophylactic antiemetic use (80 %) pre-
vented the statistical analysis of the influence of their use 
on the association between bendamustine exposure and 
nausea [17].
Pediatric patients with acute leukemia
In the population pharmacokinetic and pharmacodynamic 
safety analysis in 43 pediatric patients, infection was the 
only adverse event that was shown to be significantly cor-
related with bendamustine Cmax (P < 0.5). The most com-
mon infections were aspergillosis (n = 2, 120 mg/m2), 
sinusitis (n = 1 each, 90 and 120 mg/m2), and staphylococ-
cal infection (n = 2, 120 mg/m2). The most common grade 
3/4 infections were the two patients with aspergillosis and 
two with staphylococcal infection. As expected, the risk of 
developing an infection was greater in the absence of pro-
phylactic antibiotic use (n = 9). No other exposure meas-
ures were a significant predictor of developing an infection 
[27].
Potential for drug–drug interactions 
between bendamustine and monoclonal antibodies
Although not currently approved as combination therapy, 
bendamustine has demonstrated improved overall response 
rates and progression-free survival when combined with 
rituximab and/or other chemotherapeutic agents in the 
treatment of lymphoid malignancies [9, 43–45]. Based on 
the pharmacokinetic characteristics of bendamustine and 
rituximab, a drug–drug interaction would not typically be 
expected. However, no formal clinical pharmacology study 
has been conducted to specifically assess pharmacokinetic 
interactions between bendamustine and other drugs. Fur-
thermore, there are limited data on the pharmacokinetics 
of rituximab when combined with other drugs and on vari-
ables influencing individual exposure [46–48].
As noted before, bendamustine is a small molecule that 
is approximately 95 % bound to plasma proteins, mainly 
albumin [7, 19], and is primarily metabolized via hydroly-
sis [7, 14, 23]. In contrast, rituximab is a large molecule 
with targeted binding to CD20 antigen (but not to plasma 
proteins, such as albumin); a low volume of distribution 
(<3 L); and distinct elimination pathways that include 
hepatic proteolysis, the reticuloendothelial system, target-
mediated elimination, and endocytosis [49–51]. How-
ever, the possibility of drug–drug interactions between 
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bendamustine and rituximab cannot be completely ruled 
out. Indeed, indirect pharmacokinetic interactions between 
small molecules and monoclonal antibodies have been 
reported [48].
Two recent studies and data from the literature indicate 
that the potential for a drug–drug interaction between ben-
damustine and rituximab is low [52]. One of the studies 
was an open-label, multicenter, phase 3 study in adults who 
received bendamustine–rituximab combination therapy for 
advanced indolent NHL or mantle cell lymphoma [52]. The 
other study, which served as the data source for the ben-
damustine population pharmacokinetic model used in the 
combination therapy study, was the aforementioned phase 
3 NHL study in adults who received bendamustine mono-
therapy [17].
Bendamustine–rituximab combination therapy study
In the bendamustine–rituximab combination therapy study, 
patients received rituximab (375 mg/m2) followed by ben-
damustine (90 mg/m2) on day 1 of each cycle and benda-
mustine (90 mg/m2) on day 2 of each cycle. The final anal-
ysis dataset included bendamustine concentration samples 
from 49 patients and rituximab concentration samples from 
19 patients [52].
Bendamustine monotherapy study
In the bendamustine monotherapy study, patients received 
bendamustine (120 mg/m2) on days 1 and 2 of each 
cycle. Bendamustine plasma concentrations from 78 adult 
patients were described in a three-compartment, open pop-
ulation pharmacokinetic model with zero-order input and 
first-order elimination [17, 52].
Effect of rituximab on bendamustine pharmacokinetics
Model-predicted Bayesian estimates of bendamustine 
clearance showed similar clearance values in patients who 
received bendamustine with or without rituximab, with 
median differences within 3.4 % of each other (32.9 vs. 
31.8 L/h, respectively). The two groups did not differ sig-
nificantly in their log-transformed clearance values (two-
sided Wilcoxon signed rank test, P > 0.93) [52]. This find-
ing is consistent with results of two small Japanese studies, 
in which the pharmacokinetic profile of bendamustine 
monotherapy was observed to be comparable with that of 
bendamustine in the presence of rituximab [28, 29].
Effect of bendamustine on rituximab pharmacokinetics
Comparison between observed serum rituximab concen-
trations from the bendamustine–rituximab combination 
therapy study and those in four publications on the phar-
macokinetics of rituximab (without bendamustine) in six 
different populations suggests that bendamustine does not 
affect the systemic exposure to rituximab [52–56]. For all 
studies, rituximab concentrations were compared at end of 
infusion (in the bendamustine–rituximab study, this was 
prior to bendamustine infusion, i.e., rituximab alone), 24 h, 
and 7 days post infusion. Median observed serum rituxi-
mab concentrations, in the absence (end of infusion) and 
presence of bendamustine (24 h and 7 days post infusion), 
in the bendamustine–rituximab combination therapy study 
were consistently lower than median weighted averages 
from literature data by 24, 30, and 53 % at each respec-
tive time point. However, the relative changes in serum 
concentrations over time were generally consistent across 
the studies [52–56]. Disparities in technique (e.g., dura-
tion of rituximab intravenous infusion, assay methodology, 
or assay sensitivity) could have resulted in the differences 
between the rituximab monotherapy findings across the 
studies [52].
Conclusions
Maximal concentrations of bendamustine are typically 
reached at the end of infusion (~1 h), with rapid elimina-
tion characterized by an effective t1/2 of ~40 min and with 
no expected accumulation after multiple daily doses [7, 
14, 17]. The compound is rapidly distributed to the site of 
action, but not extensively distributed into tissues [7, 17]. 
It primarily undergoes hydrolytic metabolism (without 
hepatic enzymes), into HP1 and HP2 metabolites, which 
have little or no activity [7, 14]. The active metabolites, 
M3 and M4, are formed via a hepatic CYP1A2 oxidative 
pathway [16]; however, their contributions to the cytotoxic 
effect of bendamustine is minimal [7, 16, 18]. In addition, 
renal elimination is minor; only ~3 % of a bendamustine 
dose is excreted in urine [18, 32].
Systemic exposure to bendamustine is similar in adults 
and pediatric patients [17, 27], which confirms the appro-
priateness of BSA-based dosing [27]. Age, sex, and race 
have minimal effects on the systemic exposure to benda-
mustine [7, 17, 27].
Bendamustine is not easily displaced by and does not 
displace other highly protein-bound drugs [19] and has a 
low likelihood of direct or indirect drug–drug interactions 
[52]. Based on in vitro and clinical data, Cmax seems to be 
an important predictor of response to bendamustine [17, 
42]. No clear dose–response relationship to efficacy has 
been observed, while higher doses may be associated with 
increased risk of nausea or infection [17, 27].
Bendamustine is a unique alkylator with demonstrated 
efficacy in NHL and CLL as well as clinical activity in a 
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wide range of other malignancies [1–7]. Clinical experi-
ence with bendamustine has been extensive, and, together 
with its overall pharmacokinetics, pharmacokinetic/phar-
macodynamic relationships, and drug–drug interactions, 
support the appropriateness of a BSA-based dosing scheme 
for a wide range of patient populations.
Acknowledgments This research was sponsored by and conducted 
by Teva Branded Pharmaceutical Products R&D Inc., Frazer, PA. 
Funding for editorial, design, and production support was provided 
by Teva Branded Pharmaceutical Products R&D, Inc., to The Curry 
Rockefeller Group, LLC, Tarrytown, NY.
Conflict of interest At the time this study was conducted, M. Dar-
wish was a salaried employee at Teva Branded Pharmaceutical Prod-
ucts R&D, Inc. M. Bond, E. Hellriegel, P. Robertson, Jr., and J. P. Cho-
van are employed by Teva Branded Pharmaceutical Products R&D, 
Inc.; Hellriegel and Robertson, Jr., own stock/options in the company.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution License which permits any use, distribu-
tion, and reproduction in any medium, provided the original author(s) 
and the source are credited.
References
 1. Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (Tre-
anda) displays a distinct pattern of cytotoxicity and unique 
mechanistic features compared with other alkylating agents. Clin 
Cancer Res 14:309–317
 2. Fowler N, Kahl BS, Lee P et al (2011) Bortezomib, bendamus-
tine, and rituximab in patients with relapsed or refractory folli-
cular lymphoma: the phase II VERTICAL study. J Clin Oncol 
29:3389–3395
 3. Friedberg JW, Cohen P, Chen L et al (2008) Bendamustine in 
patients with rituximab-refractory indolent and transformed 
non-Hodgkin’s lymphoma: results from a phase II multicenter, 
single-agent study. J Clin Oncol 26:204–210
 4. Pönisch W, Rozanski M, Goldschmidt H et al (2008) Combined 
bendamustine, prednisolone and thalidomide for refractory or 
relapsed multiple myeloma after autologous stem-cell transplan-
tation or conventional chemotherapy: results of a phase I clinical 
trial. Br J Haematol 143:191–200
 5. Ohmachi K, Ando K, Ogura M et al (2010) Multicenter phase II 
study of bendamustine for relapsed or refractory indolent B-cell 
non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 
101:2059–2064
 6. Warsch S, Hosein PJ, Maeda LS, Alizadeh AA, Lossos IS (2012) 
A retrospective study evaluating the efficacy and safety of ben-
damustine in the treatment of mantle cell lymphoma. Leuk Lym-
phoma 53:1299–1305
 7. Teva Branded Pharmaceutical Products R&D, Inc (2013) TRE-
ANDA®
 (bendamustine hydrochloride) prescribing information 
http://treandahcp.com/PDF/TREANDA_final_PI.pdf. Accessed 
28 Oct 2014
 8. Knauf WU, Lissichkov T, Aldaoud A et al (2009) Phase III ran-
domized study of bendamustine compared with chlorambucil in 
previously untreated patients with chronic lymphocytic leuke-
mia. J Clin Oncol 27:4378–4384
 9. Robinson KS, Williams ME, van der Jagt RH et al (2008) Phase 
II multicenter study of bendamustine plus rituximab in patients 
with relapsed indolent B-cell and mantle cell non-Hodgkin’s 
lymphoma. J Clin Oncol 26:4473–4479
 10. Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) 
Bendamustine hydrochloride activity against doxorubicin-
resistant human breast carcinoma cell lines. Anticancer Drugs 
7:415–421
 11. Ozegowski W, Krebs D (1971) IMET 3393, γ-[1-methyl-5-
bis(β-chloroethyl)-amino-benzimidazolyl-2]-butyric acid hydro-
chloride, a new cytostatic agent from among the series of ben-
zimidazole mustard compounds. Zbl Pharm 110:1013–1019 [in 
German]
 12. Hirschberg E, Gellhorn A, Gump WS (1957) Laboratory evalu-
ation of a new nitrogen mustard, 2-[di-(2-chloroethyl)amino-
methyl]benzimidazole, and of other 2-chloroethyl compounds. 
Cancer Res 17:904–910
 13. Woolley DW (1944) Some biological effects produced by 
benzimidazole and their reversal by purines. J Biol Chem 
152:225–232
 14. Preiss R, Sohr R, Matthias M, Brockmann B, Huller H (1985) 
The pharmacokinetics of bendamustine (Cytostasane) in 
humans. Pharmazie 40:782–784
 15. Weber H, Amlacher R, Preiss R, Hoffmann H (1991) Pharma-
cokinetics of bendamustine (Cytostasan) in B6D2F1-mice. 
Pharmazie 46:589–591 [in German]
 16. Teichert J, Baumann F, Chao Q et al (2007) Characterization of 
two phase I metabolites of bendamustine in human liver micro-
somes and in cancer patients treated with bendamustine hydro-
chloride. Cancer Chemother Pharmacol 59:759–770
 17. Owen JS, Melhem M, Passarell JA, D’Andrea D, Darwish M, 
Kahl B (2010) Bendamustine pharmacokinetic profile and expo-
sure-response relationships in patients with indolent non-Hodg-
kin’s lymphoma. Cancer Chemother Pharmacol 66:1039–1049
 18. Dubbelman A-C, Rosing H, Darwish M et al (2013) Pharma-
cokinetics and excretion of 14C-bendamustine in patients with 
relapsed or refractory malignancy. Drugs R D 13:17–28
 19. Haase D, Preiss R, Sohr R (1990) Untersuchungen zur plasmaei-
weisbindung von bendamustin (Cytostasan) und ambazone. Z 
Klin Med 45:1267–1271
 20. Bezek S, Kukan M, Scasnár V, Lukácsová M, Trnovec T (1996) 
Selective uptake of the anticancer drug bendamustine by liver 
and kidney tissues following its intravenous administration to 
mice. Methods Find Exp Clin Pharmacol 18:117–122
 21. Kanekal S, Crain B, Elliott G (2004) SDX-105 (Treanda™) 
enhances the tumor growth inhibitory effect of rituximab in 
Daudi lymphoma xenografts. Blood (ASH Annual Meeting 
Abstracts) 104:229b. [Abstract 4580]
 22. Ackler S, Mitten MJ, Chen J et al (2012) Navitoclax (ABT-
263) and bendamustine±rituximab induce enhanced killing 
of non-Hodgkin’s lymphoma tumours in vivo. Br J Pharmacol 
167:881–891
 23. Dubbelman A-C, Jansen RS, Rosing H, Darwish M, Hellriegel 
E, Robertson P Jr, Schellens JHM, Beijnen JH (2012) Metabolite 
profiling of bendamustine in urine of cancer patients after admin-
istration of [14C]bendamustine. Drug Metab Dispos 40:1297–1307
 24. Chovan JP, Li F, Yu E, Ring SC (2007) Metabolic profile of [14C]
bendamustine in rat urine and bile: preliminary structural identi-
fication of metabolites. Drug Metab Dispos 35:1744–1753
 25. Beumer JH, Beijnen JH, Schellens JH (2006) Mass balance 
studies, with a focus on anticancer drugs. Clin Pharmacokinet 
45:33–58
 26. Fraser C, Brown P, Megason G et al (2014) Open-label benda-
mustine monotherapy for pediatric patients with relapsed or 
refractory acute leukemia: efficacy and tolerability. J Pediatr 
Hematol Oncol 36:e212–e218
 27. Darwish M, Megason G, Bond M, Hellriegel E, Robertson P Jr, 
Grasela T, Phillips L (2014) Population pharmacokinetics and 
1154 Cancer Chemother Pharmacol (2015) 75:1143–1154
1 3
pharmacokinetic/pharmacodynamics of bendamustine in pediat-
ric patients with relapsed/refractory acute leukemia. Curr Med 
Res Opin 30(11):2305–2315. doi:10.1185/03007995.2014.9419
76
 28. Ogura M, Uchida T, Taniwaki M et al (2010) Phase I and phar-
macokinetic study of bendamustine hydrochloride in relapsed or 
refractory indolent B-cell non-Hodgkin lymphoma and mantle 
cell lymphoma. Cancer Sci 101:2054–2058
 29. Ogura M, Ando K, Taniwaki M et al (2011) Feasibility and phar-
macokinetic study of bendamustine hydrochloride in combina-
tion with rituximab in relapsed or refractory aggressive B cell 
non-Hodgkin’s lymphoma. Cancer Sci 102:1687–1692
 30. Schoppmeyer K, Kreth F, Wiedmann M, Mössner J, Preiss R, 
Caca K (2007) A pilot study of bendamustine in advanced bile 
duct cancer. Anticancer Drugs 18:697–702
 31. McCloskey JK, Broome CM, Cheson BD (2013) Safe and effec-
tive treatment of aggressive non-Hodgkin lymphoma with rituxi-
mab and bendamustine in patients with severe liver impairment. 
Clin Adv Hematol Oncol 11:184–188
 32. Preiss R, Teichert J, Pönisch W, Niederwieser D, Matthias 
M, Merkle K (2003) Bendamustine in patients with multiple 
myeloma and renal insufficiency. Onkologie 26:S131 [Abstract 
P717]
 33. Nordstrom BL, Knopf KB, Teltsch DY, Engle R, Beygi H, 
Sterchele JA (2014) The safety of bendamustine in patients with 
chronic lymphocytic leukemia or non-Hodgkin lymphoma and 
concomitant renal impairment: a retrospective electronic medical 
record database analysis. Leuk Lymphoma 55:1266–1273. doi: 
10.3109/10428194.2013.836600
 34. Pönisch W, Andrea M, Wagner I et al (2012) Successful treat-
ment of patients with newly diagnosed/untreated multiple mye-
loma and advanced renal failure using bortezomib in combina-
tion with bendamustine and prednisone. J Cancer Res Clin Oncol 
138:1405–1412
 35. Pönisch W, Moll B, Bourgeois M et al (2013) Bendamustine and 
prednisone in combination with bortezomib (BPV) in the treat-
ment of patients with relapsed or refractory multiple myeloma 
and light chain-induced renal failure. J Cancer Res Clin Oncol 
139:1937–1946
 36. Ramasamy K, Hazel B, Mahmood S, Corderoy S, Schey S 
(2011) Bendamustine in combination with thalidomide and 
dexamethasone is an effective therapy for myeloma patients with 
end stage renal disease. Br J Haematol 155:632–634
 37. National Kidney Foundation, Inc (2002) Part 4. Definition and 
classification of stages of chronic kidney disease. Am J Kidney 
Dis 39:S46–S75
 38. Gale RP, Caligaris-Cappio F, Dighiero G, Keating M, Montserrat 
E, Rai K (1994) Recent progress in chronic lymphocytic leuke-
mia. International workshop on chronic lymphocytic leukemia. 
Leukemia 8:1610–1614
 39. Wolowiec D, Benchaib M, Pernas P et al (1995) Expression of 
cell cycle regulatory proteins in chronic lymphocytic leukemias. 
Comparison with non-Hodgkin’s lymphomas and non-neoplastic 
lymphoid tissue. Leukemia 9:1382–1388
 40. Delmer A, Ajchenbaum-Cymbalista F, Tang R et al (1995) Over-
expression of cyclin D2 in chronic B-cell malignancies. Blood 
85:2870–2876
 41. Vrhovac R, Delmer A, Tang R, Marie J-P, Zittoun R, Ajchen-
baum-Cymbalista F (1998) Prognostic significance of the cell 
cycle inhibitor p27Kip1 in chronic B-cell lymphocytic leukemia. 
Blood 91:4694–4700
 42. Schwänen C, Hecker T, Hübinger G et al (2002) In vitro evalu-
ation of bendamustine induced apoptosis in B-chronic lympho-
cytic leukemia. Leukemia 16:2096–2105
 43. Rummel MJ, Al-Batran SE, Kim SZ et al (2005) Bendamustine 
plus rituximab is effective and has a favorable toxicity profile in 
the treatment of mantle cell and low-grade non-Hodgkin’s lym-
phoma. J Clin Oncol 23:3383–3389
 44. Rummel MJ, Niederle N, Maschmeyer G et al (2013) Benda-
mustine plus rituximab versus CHOP plus rituximab as first-line 
treatment for patients with indolent and mantle-cell lymphomas: 
an open-label, multicentre, randomised, phase 3 non-inferiority 
trial. Lancet 381:1203–1210
 45. Flinn IW, van der Jagt R, Kahl BS et al (2014) Open-label, ran-
domized, noninferiority study of bendamustine–rituximab or 
R-CHOP/R-CVP in first-line treatment of advanced indolent 
NHL or MCL: the BRIGHT study. Blood 123:2944–2952
 46. Blasco H, Chatelut E, de Bretagne IB, Congy-Jolivet N, Le 
Guellec C (2009) Pharmacokinetics of rituximab associated with 
CHOP chemotherapy in B-cell non-Hodgkin’s lymphoma. Fun-
dam Clin Pharmacol 23:601–608
 47. Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C (2007) 
Pharmacokinetics of rituximab and its clinical use: thought for 
the best use? Crit Rev Oncol Hematol 62:43–52
 48. Seitz K, Zhou H (2007) Pharmacokinetic drug–drug interaction 
potentials for therapeutic monoclonal antibodies: reality check. J 
Clin Pharmacol 47:1104–1118
 49. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH (2010) Clini-
cal pharmacokinetics of therapeutic monoclonal antibodies. Clin 
Pharmacokinet 49:493–507
 50. Ng CM, Bruno R, Combs D, Davies B (2005) Population phar-
macokinetics of rituximab (anti-CD20 monoclonal antibody) in 
rheumatoid arthritis patients during a phase II clinical trial. J 
Clin Pharmacol 45:792–801
 51. Li J, Levi M, Charoin J-E et al (2007) Rituximab exhibits a long 
half-life based on a population pharmacokinetic analysis in non-
Hodgkin’s lymphoma (NHL) patients. Blood 110:700 [Abstract 
2371]
 52. Darwish M, Burke JM, Hellriegel E et al (2014) An evaluation 
of the potential for drug-drug interactions between bendamustine 
and rituximab in indolent non-Hodgkin lymphoma and mantle 
cell lymphoma. Cancer Chemother Pharmacol 73:1119–1127. 
doi:10.1007/s00280-014-2445-5
 53. Regazzi MB, Iacona I, Avanzini MA et al (2005) Pharmacoki-
netic behavior of rituximab: a study of different schedules of 
administration for heterogeneous clinical settings. Ther Drug 
Monit 27:785–792
 54. Berinstein NL, Grillo-López AJ, White CA et al (1998) Asso-
ciation of serum rituximab (IDEC-C2B8) concentration and anti-
tumor response in the treatment of recurrent low-grade or fol-
licular non-Hodgkin’s lymphoma. Ann Oncol 9:995–1001
 55. Iacona I, Lazzarino M, Avanzini MA et al (2000) Rituximab 
(IDEC-C2B8): validation of a sensitive enzyme-linked immu-
noassay applied to a clinical pharmacokinetic study. Ther Drug 
Monit 22:295–301
 56. Lazzarino M, Arcaini L, Bernasconi P et al (2002) A sequence of 
immune-chemotherapy with rituximab, mobilization of in vivo 
purged stem cells, high-dose chemotherapy and autotransplant is 
an effective and non-toxic treatment for advanced follicular and 
mantle cell lymphoma. Br J Haematol 116:229–235
